c="SSCP detection" 1:0 1:1||t="treatment"||cui="C1511790"||tot="Detection"||ns="-861"
c="osteogenesis imperfecta type II" 1:15 1:18||t="problem"||cui="C0268358"||tot="Osteogenesis imperfecta, perinatal lethal"||ns="-1000"
c="perinatal lethal osteogenesis imperfecta (OI) type II" 2:3 2:9||t="problem"||cui="C0268358"||tot="Osteogenesis imperfecta, perinatal lethal"||ns="-901"
c="alpha 1 cyanogen bromide peptide 7" 2:39 2:44||t="test"||cui="C0010511"||tot="Cyanogen Bromide"||ns="-827"
c="heterozygous transversion" 2:104 2:105||t="problem"||cui="C1705167"||tot="Nucleotide Transversion Abnormality"||ns="-861"
c="DNA sequence analysis" 2:121 2:123||t="test"||cui="C0162802"||tot="Sequence Analysis, DNA"||ns="-1000"
c="glycine-565" 2:130 2:130||t="medication"||cui="C0017890"||tot="Glycine"||ns="-861"
c="repeating Gly-Xaa-Yaa" 2:137 2:138||t="medication"||cui="C0017890"||tot="Glycine"||ns="-645"
